(redirected from Formulex)
Also found in: Dictionary.


an anticholinergic and antimuscarinic with effects similar to those of atropine; the hydrochloride salt is used as a gastrointestinal antispasmodic.

dicyclomine (dicycloverine (UK))

Bentyl, Bentylol (CA), Diclophen (CA), Formulex (CA), Lomine (CA), Merbentyl (UK), Protylol (CA)

Pharmacologic class: Anticholinergic

Therapeutic class: Antispasmodic

Pregnancy risk category B


Thought to exert direct effect on GI smooth muscle by inhibiting acetylcholine at receptor sites, thereby reducing GI tract motility and tone


Capsules: 10 mg

Solution for injection: 10 mg/ml

Syrup: 10 mg/5 ml

Tablets: 20 mg

Indications and dosages

Irritable bowel syndrome in patients unresponsive to usual interventions

Adults: 20 mg P.O. or I.M. q.i.d.; may increase up to 160 mg/day


• Hypersensitivity to drug
• GI or genitourinary tract obstruction
• Severe ulcerative colitis
• Reflux esophagitis
• Unstable cardiovascular status
• Glaucoma
• Myasthenia gravis


/di·cy·clo·mine/ (-si´klo-mēn) an anticholinergic, used as the hydrochloride salt as a gastrointestinal antispasmodic.


An anticholinergic drug, C19H35NO2, used in its hydrochloride form to relax smooth muscle and as an antispasmodic in the treatment of irritable bowel syndrome and other gastrointestinal disorders.


an anticholinergic; the hydrochloride is used as a gastrointestinal antispasmodic.
References in periodicals archive ?
We are excited that our strong intellectual property portfolio has led to a marketing agreement with M2 Formulex Inc.
IntePharm), +1-978-696-0020; or Michael Chernyak of M2 Formulex, Inc.
provides contract manufacturing and drug development services to multinational pharmaceutical and biotech companies through its PanGeo Quebec and Formulex Canada (www.
Pharmex provides contract manufacturing services to large pharmaceutical companies through its Formulex Canada (www.
PIL-CDNX) is pleased to announce that the closing of Pharmex's acquisition of the Formulex Canada Group of Companies ("Formulex") has been completed.
Formulex manufactures and distributes a number of branded pharmaceutical products for which it owns both DINs and trademarks, including among others:
Formulex achieved sales in its most recent financial year of approximately $14 million and EBITDA of $1.